Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29552271 | 1.00 | CXCR4 (0.53) | CXCR4JAK2KCNH2SMN1; SMN2HTT | |
| SCHEMBL20524435 | 1.00 | CXCR4 (0.53) | CXCR4JAK2KCNH2SMN1; SMN2HTT | |
| SCHEMBL23140153 | 0.91 | CXCR4 (0.46) | CXCR4JAK2KCNH2SMN1; SMN2JAK3 | |
| SCHEMBL29892433 | 0.89 | CXCR4 (0.67) | CXCR4JAK2KCNH2SMN1; SMN2HTT | |
| SCHEMBL31679393 | 0.89 | CXCR4 (0.67) | CXCR4JAK2KCNH2SMN1; SMN2HTT | |
| SCHEMBL22009968 | 0.89 | CXCR4 (0.67) | CXCR4JAK2KCNH2SMN1; SMN2HTT | |
| SCHEMBL26908105 | 0.88 | CXCR4 (0.69) | CXCR4JAK2KCNH2SMN1; SMN2HTT | |
| SCHEMBL465725 | 0.88 | CXCR4 (0.69) | CXCR4JAK2KCNH2SMN1; SMN2HTT | |
| SCHEMBL31679380 | 0.88 | CXCR4 (0.69) | CXCR4JAK2KCNH2SMN1; SMN2HTT | |
| SCHEMBL26241425 | 0.87 | CXCR4 (0.44) | CXCR4JAK2KCNH2SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025088147-A1 | THERANOSTIC PSMA-TARGETING LIGANDS FOR THE DIAGNOSIS AND TREATMENT OF PSMA-EXPRESSING CANCERS AND THEIR SOLID PHASE SYNTHESIS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-05-01 | — | — | WO | claimed |
| EP-4719499-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CD33-POSITIVE HEMATOLOGICAL MALIGNANCIES HARBORING MUTATIONS | Actinium Pharmaceuticals, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4637821-A1 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | Actinium Pharmaceuticals, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20250289875-A1 | GRP78 NANOBODIES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-20250163040-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | CORNELL UNIVERSITY (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2025088147-A1 | THERANOSTIC PSMA-TARGETING LIGANDS FOR THE DIAGNOSIS AND TREATMENT OF PSMA-EXPRESSING CANCERS AND THEIR SOLID PHASE SYNTHESIS | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2025-05-01 | — | — | WO | disclosed |
| EP-4536278-A2 | BIFUNCTIONAL CHELATORS AND CONJUGATES | Actinium Pharmaceuticals, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4493578-A1 | TARGETED DELIVERY OF THERANOSTIC AGENTS | Peter MacCallum Cancer Institute (AU) | 2025-01-22 | — | — | EP | disclosed |
| WO-2024250014-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CD33-POSITIVE HEMATOLOGICAL MALIGNANCIES HARBORING MUTATIONS | ACTINIUM PHARMACEUTICALS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024243315-A2 | MULTI-ARM BIFUNCTIONAL CHELATORS | ACTINIUM PHARMACEUTICALS, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024055040-A2 | HUMANIZED ANTI-CD45 ANTIBODIES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023240135-A2 | BIFUNCTIONAL CHELATORS AND CONJUGATES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023220643-A2 | GRP78 NANOBODIES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4251214-A2 | METHODS FOR TREATING CANCER USING COMBINATIONS OF EPIGENETIC THERAPIES AND RADIOCONJUGATE TARGETING AGENTS | Actinium Pharmaceuticals, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023183944-A2 | HER3 NANOBODIES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| EP-4247430-A1 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | Actinium Pharmaceuticals, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023173174-A1 | TARGETED DELIVERY OF THERANOSTIC AGENTS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023137335-A2 | METHODS FOR TREATING CD33-POSITIVE HEMATOLOGICAL MALIGNANCIES | ACTINIUM PHARMACEUTICALS, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2022115664-A2 | METHODS FOR TREATING CANCER USING COMBINATIONS OF EPIGENETIC THERAPIES AND RADIOCONJUGATE TARGETING AGENTS | ACTINIUM PHARMACEUTICALS, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022109404-A1 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | ACTINIUM PHARMACEUTICALS, INC. (US) | 2022-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163040-A1 | MACROCYCLIC COMPLEXES OF ALPHA-EMITTING RADIONUCLIDES AND THEIR USE IN TARGETED RADIOTHERAPY OF CANCER | PSMA1, FOLH1, KLK3 | CXCR4 2897/4885JAK2 2830/4885KCNH2 3819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.